MTF Biologics, a global nonprofit organization dedicated to saving and healing lives through organ and tissue donation, is introducing Leneva™ – Allograft Adipose Matrix and SomaGen™ Meshed – Allograft Dermal Matrix to its line of premier, innovative and effective wound care solutions.
Developed to advance the treatment of complex surgical wounds, these first-to-market tissue forms aid in tissue reconstruction and wound closure by providing protective coverage and promoting tissue integration.
“We are thrilled to add both Leneva and SomaGen Meshed to our portfolio of innovative natural wound care solutions to meet the needs of patients with chronic and complex wounds,” said Kim Rounds, Vice President of Wound Care at MTF Biologics. “The recurrence of chronic and complex wounds are painful and can be both life-threatening and costly to treat.” Marc Long, PhD, Vice President of Research and Development at MTF Biologics added, “With the novelty of our adipose technology along with our unique and patented deep-reticular meshed dermal tissue, we will add to our ever-growing family tree. We are proud to continue to harness the power of allograft tissue, and to branch out to create the world’s most well-rounded and innovative set of biologic solutions for treating even the most complex wounds.”
Leneva is an all-natural, extracellular adipose matrix for various tissue reconstruction procedures that:
- Supports the patient’s tissue reconstruction process;
- Is provided hydrated to reduce procedural preparation time; and
- Provides an extracellular adipose matrix that functions as a scaffold for patient cells to create new fat.
Derived from donated human adipose, Leneva is aseptically processed, allowing the final adipose matrix to maintain sterility and the structural integrity of the tissue. Free from residual lipid, cellular fragments and DNA content, Leneva retains key matrix proteins including Collagen IV and Collagen VI, and is injected where native fat already exists to provide soft tissue augmentation and cell attachment and remodeling. Clinical studies on the use of Leneva to treat fat pad insufficiencies associated with ulcers have shown a reduction in peak mean pressure, which indicates a reduction in callus formation. Other studies on the use of Leneva in vivo show that it supports host cell infiltration and the development of new blood vessels and fat-storing cells.
SomaGen Meshed is an acellular human reticular dermal allograft that supports the treatment of a variety of large and complex wounds. As the only allograft tissue comprised of meshed reticular dermis on the market, SomaGen:
- Expands up to 150 percent to accommodate wounds of various sizes;
- Is ideal for areas where skin has been taken to cover wounds on another part of the body;
- Conforms and expands to the wound and topography to provide immediate coverage;
- Aids in the healing of wounds by improving drainage; and
- Provides a scaffold for wound closure to allow a patient’s own cells to proliferate and repopulate the graft and facilitate integration.
The unique, lattice-based slit design may also eliminate the need for autologous skin grafting and manual meshing equipment in the operating room, lowering costs and reducing procedure time.
MTF Biologics will introduce SomaGen Meshed and Leneva at the 2019 Desert Foot Annual Multi-Disciplinary Limb Salvage and Wound Care Conference in Phoenix from December 4-7. MTF Biologics will also host an industry sponsored symposium – titled “Different by Design: New Biologic Innovations for Complex Surgical Wound Management” – on Wednesday, Dec. 4 from 8:30 a.m. – 9:10 a.m. In addition to the solutions’ unveiling, the symposium will feature case presentations that outline the science of tissue forms and their clinical applications. Immediately following the symposium, MTF Biologics will host an educational workshop on how to utilize these two tissues with Drs. Michael Desvigne and Jodi Schoenhaus.
For more information, visit www.mtfbiologics.org